Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Effects of food on the bioequivalence of different verapamil sustained-release formulations.

Waldman SA, Morganroth J.

J Clin Pharmacol. 1995 Feb;35(2):163-9.

PMID:
7751427
2.
3.

Bioequivalence of controlled-release calcium antagonists.

Schall R, Müller FR, Müller FO, Luus HG.

Clin Pharmacokinet. 1997 Jan;32(1):75-89. Review.

PMID:
9012557
4.

The bioequivalence of highly variable drugs and drug products.

Midha KK, Rawson MJ, Hubbard JW.

Int J Clin Pharmacol Ther. 2005 Oct;43(10):485-98. Review.

PMID:
16240706
5.

Generic cyclosporine formulations: more open questions than answers.

Cattaneo D, Perico N, Remuzzi G.

Transpl Int. 2005 Apr;18(4):371-8. Review.

6.

Selection of a slow-release theophylline product.

Hendeles L, Weinberger M.

J Allergy Clin Immunol. 1986 Oct;78(4 Pt 2):743-51. Review.

PMID:
3534055
7.

Variability and impact on design of bioequivalence studies.

Van Peer A.

Basic Clin Pharmacol Toxicol. 2010 Mar;106(3):146-53. doi: 10.1111/j.1742-7843.2009.00485.x. Epub 2009 Nov 11. Review.

8.

Drug substitution in transplantation: a National Kidney Foundation White Paper.

Sabatini S, Ferguson RM, Helderman JH, Hull AR, Kirkpatrick BS, Barr WH.

Am J Kidney Dis. 1999 Feb;33(2):389-97. Review.

PMID:
10023656
9.

Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products by the US Food and Drug Administration.

Davit BM, Chen ML, Conner DP, Haidar SH, Kim S, Lee CH, Lionberger RA, Makhlouf FT, Nwakama PE, Patel DT, Schuirmann DJ, Yu LX.

AAPS J. 2012 Dec;14(4):915-24. doi: 10.1208/s12248-012-9406-x. Epub 2012 Sep 13. Review.

10.

Drug interchanges at the pharmacy: safe for cardiovascular disease?

McCue JD.

Hosp Pract (Off Ed). 1991 Jul 15;26(7):23-4, 29, 32. Review.

PMID:
2071680
11.

Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Fleisher D, Li C, Zhou Y, Pao LH, Karim A.

Clin Pharmacokinet. 1999 Mar;36(3):233-54. Review.

PMID:
10223170
12.

Controlled-release formulations of propranolol and verapamil.

Dunn J.

J Clin Pharmacol. 1987 Jan;27(1):22-31. Review.

PMID:
3316302
13.

Bioequivalence for locally acting nasal spray and nasal aerosol products: standard development and generic approval.

Li BV, Jin F, Lee SL, Bai T, Chowdhury B, Caramenico HT, Conner DP.

AAPS J. 2013 Jul;15(3):875-83. doi: 10.1208/s12248-013-9494-2. Epub 2013 May 18. Review.

14.

Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products.

Chang RK, Raw A, Lionberger R, Yu L.

AAPS J. 2013 Jan;15(1):41-52. doi: 10.1208/s12248-012-9411-0. Epub 2012 Oct 9. Review. Erratum in: AAPS J. 2015 Nov;17(6):1522.

15.

Open questions on bioequivalence: an updated reappraisal.

Marzo A.

Curr Clin Pharmacol. 2007 May;2(2):179-89. Review.

PMID:
18690864
16.

Influence of drug formulation on drug concentration-effect relationships.

Castañeda-Hernández G, Caillé G, du Souich P.

Clin Pharmacokinet. 1994 Feb;26(2):135-43. Review.

PMID:
8162657
17.

Effects of food on drug absorption.

Welling PG.

Annu Rev Nutr. 1996;16:383-415. Review.

PMID:
8839932

Supplemental Content

Support Center